A case-control study was performed to determine the effects of HIV-1-specific cellular immune responses on the odds of acquiring a second HIV-1 infection (superinfection). Changes in the frequency of cytokine-producing or cytolytic CD8 R or CD4 R T cells were not associated with significant alterations in the odds of superinfection, suggesting that HIV-1 specific cellular immune responses at the level induced by chronic infection do not appear to significantly contribute to protection from HIV-1 superinfection.
Despite 25 years of research, relatively little is known about the ability of HIV-1-specific immune responses to modulate the risk of infection in humans exposed to HIV-1. Although many studies have shown that cytotoxic T-lymphocytes (CTLs) contribute to the control of an established HIV-1 infection [1] , their role in preventing new infections are challenging to ascertain. Aside from vaccine trials, studies of superinfection provide one of the only settings to evaluate the protective role of HIV-1-specific immune responses in humans exposed to diverse, circulating strains. HIV-1 superinfection occurs when an individual infected with one strain of HIV-1 becomes infected with a second strain from a different source partner [2] . The protective role of preexisting HIV-1-specific immunity in the setting of superinfection remains unclear. In six superinfected individuals examined in prior case studies, at least some of the targeted CTL epitopes were altered in the superinfecting strain in comparison to the initial strain, potentially contributing to the ability of the superinfecting strains to establish infection despite the ongoing CTL response [3] [4] [5] [6] [7] . However, no prior studies of superinfection have compared the breadth, magnitude, or polyfunctionality of the T-cell responses among superinfected individuals and individuals who were not superinfected. To better define correlates of protection from a second HIV-1 infection, we undertook the first case-control study to assess HIV-1-specific cellular immune responses in HIV-1-infected women with continued exposure to HIV-1, some of whom went on to become superinfected. The superinfected cases (n ¼ 12) and nonsuperinfected controls (n ¼ 36) were previously identified among 56 women enrolled in a prospective cohort study of high-risk women [8] [9] [10] . Informed consent was obtained from all participants, and the Ethical Review Committees of the University of Nairobi, the University of Washington, and the Fred Hutchinson Cancer Research Center approved this study. None of the individuals were treated with antiretroviral medications or were in an advanced state of immunosuppression at the time of superinfection. Controls (three per case) were matched to cases according to the HIV-1 subtype, the timing of samples in relation to initial infection, and the viral load, as described previously [11] . Cases and controls had similar levels of ongoing reported risk for exposure to HIV-1 during the follow-up period, with an average of 1.46 sex partners per week for the cases and 1.42 sex partners per week for the controls. The sample dates ranged from 21 to 1150 days (median 285) prior to documented superinfection.
We determined the frequency of antigen-specific CD8 þ and CD4 þ T-cell responses by intracellular cytokine staining (ICS) following stimulation with HIV-1 and cytomegalovirus (CMV) peptide pools, as described previously [12, 13] . The CMV pp65 peptides, HIV-1 potential T-cell epitope (PTE) gag peptides, and HIV-1 PTE env peptides were obtained from the AIDS Research and Reference Reagent Program, National Institutes of Health (NIH); phorbol 12-myristte 13acetate/ionomycin (Sigma-Aldrich, St Louis, Missouri, USA) was used as a positive control. The following antibodies were used: CD107a-PE-Cy5, CD4-Alexa700, CD8-PerCP-Cy5.5, GranzymeB-Alexa700, interferon (IFN)-g-PE-Cy7, interleukin (IL)-2-APC, macrophage inflammatory protein (MIP)-1b-PE, tumor necrosis factor (TNF)-a-FITC (BD Biosciences, San Jose, California, USA), and CD3-Qdot605 (Molecular Probes, Grand Island, New York, USA). The percentage of CD8 þ and CD4 þ T cells producing the cytokines IL-2, TNFa, IFNg, and MIP-1b was determined. Cytolytic activity was also assessed based on expression of CD107a, using Granzyme B expression to confirm that degranulating CD107a þ CD8 þ T cells had cytolytic potential [14] . Data were analyzed using FlowJo, version 9.1 (Tree Star Inc., Ashland, Oregon, USA), and background from wells stimulated with dimethyl sulfoxide alone was subtracted. Samples were rejected for 10 of the 48 participants for low viability (<50% after resting and stimulation) and/or for low cell numbers (<1000 live CD4 þ or CD8 þ T cells), leaving 10 superinfection cases and 28 controls. Of the superinfection cases evaluated, three were superinfected with a virus of the same subtype ISSN 0269-9370 Q 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins (intrasubtype superinfection), whereas seven were intersubtype superinfections. Cytokine production and cytolytic activity were similar to that observed in other cohorts of chronically HIV-1-infected individuals [15] [16] [17] [18] [19] [20] .
To determine whether individuals with deficits in T-cell functions were more likely to be superinfected, the odds of superinfection were evaluated in relation to T-cell function by exact conditional logistic regression ( Table 1) . For cases, analyses were performed using samples collected at the visit prior to documented superinfection in order to assess immunity at the time point most relevant in terms of exposure to, and lack of protection from, the second virus. The samples for the controls were taken from approximately the same time following initial infection. Statistical analyses were performed using the Open Source statistical package R (http://www.rproject.org; ISBN 3-900051-07-0) and LogXact (Cytel Incorporated, Cambridge, Massachusetts, USA). Overall, changes in the frequency of cytokine-producing or cytolytic CD8 þ or CD4 þ T cells were not associated with significant alterations in the odds of superinfection (Table  1 ). For instance, the odds of being superinfected were a negligible 1.02 times greater (95% confidence interval 0.95-1.09) for every increase of 0.1 in the percentage of CD8 þ T cells expressing CD107a following stimulation with gag peptides, with a P-value of 0.47 (Table 1) . Similar results were observed for every other function of CD8 þ and CD4 þ T cells, including the production of IFNg, IL-2, MIP-1b, or TNFa, and for every possible combination of functions as determined by Boolean gating (Table 1 and data not shown). Thus, CD8 or CD4 T-cell responses to global HIV-1 peptide pools were not significantly associated with the odds of superinfection.
These findings are admittedly disappointing: there is little evidence that HIV-1-specific cellular immune responses, at least at the level observed during chronic infection, play a significant role in protection from HIV-1 acquisition in the setting of superinfection. Similar results were recently attained in simian immunodeficiency virus-infected macaques in which CTL contributed to the control of chronic infection, but not to protection from superinfection [21] . Although these data do not necessarily mean that HIV-specific T cells are incapable of contributing to protection from HIV-1, they do suggest that protection may require T cells at higher frequency or with different specificity than those found in chronically HIV-1-infected individuals. Further studies of humans exposed to diverse HIV-1 strains are therefore necessary to determine which immune responses, if any, contribute to protection.
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AIDS 2012, Vol 26 No 5 Because sexually transmitted infections (STIs) increase HIV transmission [1] [2] [3] , HIV-infected patients and their partners benefit from early detection of STI. A study at two university HIV clinics in the Netherlands found that 16% of HIV-infected men who have sex with men (MSM) had asymptomatic STI [4] , indicating that MSM would benefit from regular STI screening. However, its value for HIV-infected heterosexual men and women is unclear. Among such patients in the USA, the prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae, tested in HIV clinics, varied between 0% and 5% [5] [6] [7] . The prevalence among these patients in other high-income countries has not been investigated recently.
In 2007 and 2008, we studied heterosexual patients who attended the HIV outpatient clinic of the Academic Medical Center (AMC) in Amsterdam for a routine visit.
The study was approved by the AMC medical ethics committee and written informed consent was obtained. Whether or not they were sexually active, patients were eligible if they were aged 18 years and older, could understand Dutch, English or French and had not spontaneously reported STI symptoms at their routine visit. In case of spontaneously reported STI-related symptoms, patients were not included and referred to the STI outpatient clinic for further care. Men who indicated three or more male sexual partners in their lifetime were considered MSM and excluded. Patients were interviewed by a trained interviewer about demographics and both sexual behaviour in the preceding 6 months and lifetime. Oral, vaginal, and anal self-swabs were obtained [8, 9] , as were serum and urine samples. If a patient's blood had been sampled less than 4 months previously, and routine care did not require new sampling, the stored blood was used for serological testing.
C. trachomatis and N. gonorrhoeae were tested by Nucleic Acid Amplification Test (Gen-probe Aptima Assay, Tigris, San Diego, California, USA). Serologic testing for hepatitis B (HBV) and hepatitis C (HCV) was performed using Axsym automated enzyme immune assays (Abbott Laboratories, Chicago, Illinois, USA).
Conventional rules for diagnosis of HBV or HCV infection were applied. HBV serology was not done for patients already known to be HBsAg-positive or HBV immune after vaccination or infection. Anti-HCV was not tested in patients known to have antibodies against HCV. Patients were screened for syphilis with Treponema pallidum haemagglutination assay (TPHA) and Rapid Plasma Reagin (RPR). Diagnostic criteria for recent syphilis infection was a positive TPHA with a recently found positive RPR or a more than four-fold increase in RPR titre compared with the last measurement. Analyses were performed using STATA, version 11 (Stata Corp, College Station, Texas, USA).
Of 895 HIV-infected heterosexual patients registered at the AMC HIV outpatient clinic, 245 participated (27.4%). Not all patients who visited the outpatient clinic in the inclusion period were invited to participate due to logistical restrictions. There were no significant differences in age, sex, ethnicity, transmission route, plasma HIV RNA, CD4 cell count, combination antiretroviral therapy (cART) use or duration of cART use between participants and those who did not participate.
The median age of the total population was 41 years, range 18-82 years ( Table 1 ). All were tested for STI and 201 (82%) patients were interviewed, although some were unable or unwilling to answer all questions. Fortynine percent were married or living with a partner.
Only four of all asymptomatic patients (1.6%) were diagnosed with an STI: two women had cervical C. trachomatis, one man had urethral C. trachomatis, and a woman with a history of injecting drug use and syphilis had a new syphilis infection [negative RPR in 2006 and new positive RPR (1 : 36) in 2008]. We diagnosed no new HBV infections. We diagnosed one HCV infection in a man who was an injecting drug user. As he reported Our most important finding is that the prevalence of asymptomatic STI is very low (1.6%) in this group of HIV-infected heterosexuals. It contrasts sharply with the 16% prevalence found in a study of HIV-infected MSM performed in the same setting [4] , and with the moderate prevalence of C. trachomatis and N. gonorrhoeae found among HIV-infected women in a study done in the USA (Louisiana): 5.9% and 3.0%, respectively [7] . However, in line with our findings, studies in 1999 and 2000 in the USA found a low prevalence of C. trachomatis (1.7%) [5] , and C. trachomatis and N. gonorrhoeae (together 0.5%) [6] in HIV-infected men and women in HIV clinics. Our diagnosis of one new syphilis infection accords with other studies finding no syphilis [6] or a very low prevalence [10] in HIV-infected heterosexuals. Younger age is a risk factor for acquiring C. trachomatis [11, 12] , so age differences among studies can hinder comparisons. The finding of low prevalence in our population may be explained by the low level of high-risk sexual behaviour in interviewed participants.
Recently, HCV has emerged as an STI among HIVinfected MSM [13] . However, the HCV infection diagnosed in this study was most likely transmitted through needle sharing, and this suggests that HIVinfected heterosexuals are still not at risk of sexually acquired HCV.
Although it has previously been suggested [14] that STI screening among HIV-infected heterosexuals should be considered, our study results suggest that STI screening during routine visits of asymptomatic heterosexual patients in clinics with comparable patient groups is currently not needed. The efficacy and safety of once-daily darunavir/ ritonavir and fixed-dose abacavir/lamivudine was examined in 22 treatment-naïve patients with HIV-1 infection. Three patients discontinued antiretroviral therapy due to mild adverse events. Among 18 patients who continued therapy, 66.7% had viral load less than 50 copies/ml at week 48. Only two patients experienced virologic failure with the emergence of resistant virus. This pilot study demonstrated the viral efficacy and safety of darunavir/ritonavir and abacavir/lamivudine.
Only very little information is available on the efficacy and safety of the combination antiretroviral therapy (ART) of ritonavir-boosted darunavir (DRV/r) and fixed-dose abacavir/lamivudine (ABC/3TC) [1] . DRV/r is a protease inhibitor with proven efficacy and safety as well as with a high barrier to drug resistance [2, 3] . ABC/3TC is an alternative choice of nucleoside reverse transcriptase inhibitor (NRTI) backbone in the American Department of Health and Human Services (DHHS) Guidelines and is the other preferred backbone regimen for treatment-naïve patients in other international guidelines [4, 5] . In this pilot study, we evaluated the efficacy and safety of DRV/r and ABC/3TC for treatment-naïve patients in a single-center, observational cohort.
The participants of this retrospective study were all treatment-naïve patients with HIV infection who commenced once-daily DRV/r and fixed-dose ABC/3TC from November 2009 (when the first patient commenced such regimen at our clinic) to November 2010 at our clinic (AIDS Clinical Center, Tokyo, Japan). All patients were followed for at least 48 weeks after commencement of treatment at our facility. Baseline data, including age, sex, mode of infection, ethnicity, CD4 cell count, and HIV viral load, were collected from the medical charts. The Cobas TaqMan HIV-1 real-time PCR version 1.0 assay (Roche Diagnostics, NJ) was used to measure HIV-1 viral load throughout the research period. For those who discontinued either DRV/r or fixed-dose ABC/3TC before reaching 48 weeks, the reasons for discontinuation were collected. All patients provided written informed consent for the data to be published. Primary outcomes were the proportion of patients with viral load less than 50 copies/ml at 24 and 48 weeks. Safety parameters through 48 weeks were also collected. , whereas the HIV viral load was 5.61 log 10 copies/ml (IQR 4.57-6.01 log 10 copies/ ml). In three patients, ART was either changed or discontinued during the study due to adverse events [skin rash (n ¼ 1), vomiting (n ¼ 1), and limb paresthesia (n ¼ 1)] and one patient changed the regimen due to a concern with drug interactions with antipsychotics before 48 weeks. The skin rash was due to darunavir, because the rash disappeared after switching darunavir to raltegravir, while continuing ABC/3TC. This patient was HLA-B Ã 5701-negative. None presented with ABCassociated hypersensitivity or with grade 3 or 4 liver enzyme elevation.
On-treatment analysis of the 18 patients (excluding the above four patients who discontinued the regimen) showed 72.2% had viral load less than 50 copies/ml at week 24 (88.9% viral load <200 copies/ml), and 66.7% had viral load less than 50 copies/ml at week 48 (88.9% viral load <200 copies/ml). Intention-to-treatment analysis showed 59.0% with viral load less than 50 copies/ml at week 24 (77.3% viral load <200 copies/ml), and 54.6% with viral load less than 50 copies/ml at week 48 (72.7% viral load <200 copies/ml) ( Fig. 1) . Four patients showed rebounds greater than 200 copies/ml (<1000 copies/ml) after 24 weeks; two of them were single rebounds and were considered blips. The other two patients showed two consecutive viral load greater than 200 copies/ml, fulfilling the criteria of virological failure (11.1% at 48 weeks). The latter two patients underwent a genotypic resistance test that detected, in one case, the reverse transcriptase mutation M184V and, in the other, the protease mutation M46I.
In the 12 patients with baseline viral load above 100 000 copies/ml, on-treatment analysis showed viral load of less than 200 copies/ml at 24 weeks in 10 (83.3%) patients, and less than 50 copies/ml at both 24 and 48 weeks in seven (58.3%). In comparison, all six patients with baseline viral load below 100 000 copies/ml showed suppression of the load to below 50 copies/ml at both 24 and 48 weeks. The median increment in CD4 cell count at 48 weeks was 187/ml (IQR 82.5-264.5/ml).
Discussion
To our knowledge, this is the first published study on the efficacy and safety of the combination of once-daily DRV/r and fixed-dose ABC/3TC in treatment-naïve patients. This combination ART resulted in viral suppression, although the baseline viral load was above 100 000 copies/ml in 66.6% of the patients. Only 13.6% discontinued this regimen due to adverse events before 48 weeks and none of the adverse events was serious. Considering that most patients in this cohort were at an advanced stage of HIV infection with a low median baseline CD4 cell count of 47/ml, we conclude that DRV/r and ABC/3TC is a well tolerated and efficacious combination ART.
The DHHS guidelines for the treatment of HIV infection in the USA list ABC/3TC as alternative NRTIs since abacavir can potentially cause serious hypersensitivity reaction in 5-8% of the patients and its viral efficacy in patients with baseline viral load of above 100 000 copies/ml is inferior to fixed-dose tenofovir/emtricitabine (TDF/ FTC) when used with efavirenz or ritonavir-boosted atazanavir as a key drug [4, 6] . However, the incidence of ABC-related hypersensitivity is low among the HLA-B Ã 5701-negative population, such as the Japanese [7, 8] .
Moreover, the HEAT study demonstrated that the viral efficacy of ABC/3TC was not inferior to that of TDF/ FTC when used with lopinavir/ritonavir for treatmentnaive patients [9] . Taking this background into account, once-daily DRV/r and ABC/3TC could be a good alternative, especially in patients with a low prevalence of HLA-B Ã 5701 who cannot tolerate tenofovir due to its nephrotoxicity [10] .
In conclusion, this single-center pilot study demonstrated the viral efficacy and safety of once-daily DRV/r and ABC/ 3TC in treatment-naïve patients with HIV-1 infection. This regimen could be a suitable alternative to DRV/r and tenofovir/emtricitabine or other first-line regimens. Nevertheless, the number of patients in this cohort is too small to allow firm conclusions and further studies of larger samples (ideally a clinical trial that compares the viral efficacy of TDF/FTC to ABC/3TC with once-daily DRV/r) are needed to elucidate this issue.
